Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous versus intermittent piperacillin-tazobactam dosing in ICU trauma patients with infection
ACTRN12617000020381Phase 2Terminated
- Sponsor
- The University of Queensland
- Start
- Jul 2015
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of piperacillin + tazobactam, sponsored by The University of Queensland. Started Jul 2015; status: terminated.
02
Drugs
piperacillin + tazobactam
Beyond the preview
Go deeper on ACTRN12617000020381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000020381.